Lucira Health, Inc. Form 8-K (Dec. 29, 2021)

Summary

Current report on Form 8-K of Lucira Health, Inc. dated December 29, 2021, furnished under Item 7.01, Regulation FD Disclosure. The company states that on December 29, 2021 it issued a press release commenting on the partnership with Co-Defend, Inc. and Co-Protect, LLC. The press release is furnished as Exhibit 99.1, and the report states the information is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. Item 9.01 lists Exhibit 99.1, the press release dated December 29, 2021, and Exhibit 104, the cover page interactive data file. The signature block is Daniel George, Chief Financial Officer, dated December 29, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

December 29, 2021

Lucira Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39976 | 27-2491037
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
1412 62nd Street Emeryville , California | 94608
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (510) 350-8071

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | LHDX | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 | Regulation FD Disclosure.

On December 29, 2021, Lucira Health, Inc. (the “Company”) issued a press release commenting on its partnership with Co-Defend, Inc. and Co-Protect, LLC. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 | Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number | Exhibit Description
99.1 | Press Release dated December 29, 2021.
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lucira Health, Inc.
Date: December 29, 2021 | By: | /s/ Daniel George
Daniel George Chief Financial Officer

File and source

File

SEC_LHDX_8-K_filed2021-12-29_0001193125-21-368437.htm

Size

25,253 bytes

SHA-256

324a3877573bc8aea7e5cb737ba8cd6c73ec62e5a0fbb19994e63bd7eecd98ae

Our copy

SEC_LHDX_8-K_filed2021-12-29_0001193125-21-368437.htm

Original

www.sec.gov